Pirfenidone in rheumatoid arthritis-associated interstitial lung disease - Authors' reply

Affiliations

¹ Brigham and Women's Hospital, Boston, MA, USA.
² National Jewish Health, Denver, CO, USA.
³ Baylor College of Medicine, Houston, TX 77030, USA. Electronic address: ivan.rosas@bcm.edu.

Comment

Shelley Hurwitz et al. Lancet Respir Med. 2023 Jun.

. 2023 Jun;11(6):e52.

doi: 10.1016/S2213-2600(23)00131-5. Epub 2023 Mar 29.

¹ Brigham and Women's Hospital, Boston, MA, USA.
² National Jewish Health, Denver, CO, USA.
³ Baylor College of Medicine, Houston, TX 77030, USA. Electronic address: ivan.rosas@bcm.edu.

No abstract available

Conflict of interest statement

IOR was awarded a grant from Genentech–Roche on behalf of the TRAIL1 network. All other authors declare no competing interests.

Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study.
Solomon JJ, Danoff SK, Woodhead FA, Hurwitz S, Maurer R, Glaspole I, Dellaripa PF, Gooptu B, Vassallo R, Cox PG, Flaherty KR, Adamali HI, Gibbons MA, Troy L, Forrest IA, Lasky JA, Spencer LG, Golden J, Scholand MB, Chaudhuri N, Perrella MA, Lynch DA, Chambers DC, Kolb M, Spino C, Raghu G, Goldberg HJ, Rosas IO; TRAIL1 Network Investigators. Solomon JJ, et al. Lancet Respir Med. 2023 Jan;11(1):87-96. doi: 10.1016/S2213-2600(22)00260-0. Epub 2022 Sep 5. Lancet Respir Med. 2023. PMID: 36075242 Clinical Trial.
Pirfenidone in rheumatoid arthritis-associated interstitial lung disease.
Graudal N, Nielsen CT, Lindhardsen J. Graudal N, et al. Lancet Respir Med. 2023 Jun;11(6):e51. doi: 10.1016/S2213-2600(23)00130-3. Epub 2023 Mar 29. Lancet Respir Med. 2023. PMID: 37003283 No abstract available.